A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

Twenty-six years later, the country is facing its worst outbreak of the highly contagious disease and is on the verge of losing its hard-earned elimination status.

As of November 5, 2026, the US had reported 5,182 confirmed measles cases, according to the CDC. It is the first time that the country has crossed 5,000 mark since 1991.

Further, Pennsylvania (six), New York (one) and Wisconsin (one) have reported a combined eight measles-associated deaths this year — more than the total recorded between 2000 and 2024.

The Pan American Health Organization (PAHO), a regional office of the World Health Organization, is reviewing the country's status. An announcement is expected next week.

What Is Driving The Measles Resurgence In The US?

Also read: EXCLUSIVE: Ex-CDC Vaccine Advisor Says Measles Outbreak Bigger Than Reported, Slams RFK Jr’s ‘No-See Evil’ Approach

Vaccine hesitancy is a key factor behind the resurgence, said Professor Devi Sridhar, Professor and Chair of Global Public Health at the University of Edinburgh, in an exclusive conversation with HealthandMe.

"We're seeing more parents concerned about the side effects of vaccines. Perhaps they've seen a video online or read something that makes them nervous. So for a while in the 1990s, for example, the MMR vaccine was falsely linked to rising autism rates."

She noted that while the study has since been debunked, misinformation of this kind has contributed to vaccine hesitancy, with parents choosing not to vaccinate their children despite vaccines being available because they fear potential side effects.

Falling Vaccination Rates Allow Measles To Spread

Two doses of the MMR vaccine are approximately 97% effective at preventing measles. Even a single dose provides strong protection, offering about 93% effectiveness.

Sridhar said the number of vaccinated children was falling below the threshold needed to prevent the virus from circulating and causing deaths in the country.

"But what we're seeing is that the number of children vaccinated is falling underneath that threshold, which is around 85 to 90%. And once you get a population that is not vaccinated to that level, measles starts to circulate, then it starts to find children, and unfortunately they get infected. And because it's so serious, we are starting to see deaths even in the United States."

Sridhar also warned that misinformation online is undermining trust in vaccines. She said online claims about the MMR vaccine, including false links to autism and fears about side effects, can discourage parents from vaccinating their children.

"That's very dangerous now because as we know, the information on the internet and on social media isn't regulated."

Read More: What Happens After Measles Infection? The Hidden Risks That Can Last For Years

Can The US Rebuild Public Trust In Vaccines?

Sridhar pointed to changes in the country's public health and scientific institutions over the past two years, including the dismantling of the vaccine advisory group and a shift towards alternative therapies that has contributed to vaccine hesitancy.

However, with the recent Democratic gains in Congress, she is hopeful about the possibility of restoring science in government.

“Those who are scientifically trained, those who are doctors, clinicians, PhDs, people who have that kind of background will really help to hopefully bring science back into government and into government advice and help build that trust.”

How Is Measles-Elimination Status Determined?

PAHO considers endemic measles transmission to have been re-established when the same virus genotype and lineage circulates uninterrupted for at least 12 months within a country or defined geographical area.

The Regional Verification Commission reviews epidemiological and laboratory evidence, alongside information on vaccination coverage, surveillance and outbreak response, before making recommendations on a country's status.

Publicly available data shows that several chains of measles transmission have continued for more than a year in the US, according to scientists who analysed the data at the request of The New York Times.

Three separate transmission chains — two in Utah and one in Arizona — were continuing in July 2026 and could be traced to an outbreak in Texas more than a year earlier. One of these chains was still circulating in Utah in September, occasionally spilling over into Oregon and Washington.

Another transmission chain, detected in Virginia at the start of the year, was still spreading in Iowa, Indiana and Pennsylvania as of mid-October.

Anthropic CEO Dario Amodei has claimed that cancer, Alzheimer's disease, heart disease and mental illness could become “relics of the past” in less than a decade, thanks to artificial intelligence (AI).

The AI company has kicked off the roadshow for its US initial public offering (IPO), seeking to raise up to $64.4 billion at a valuation of around $1 trillion. The listing could mark the first public offering by a frontier AI lab.

In the company's IPO roadshow video, Amodei spoke about AI's potential to transform human health, describing a future in which diseases that have long challenged medicine could be overcome.

"I think if we do this right, we can create an age of miracles where humanity is able to solve problems that have eluded us for millennia," he said.

Amodei also addressed the risks associated with AI and invited investors to join the company's next phase of growth.

"We have to make sure that all the risks, all the ways that things can go wrong with this technology, we very carefully address those risks as we bring the benefits, and as we have a viable business at the same time".

Amodei isn't alone. His promise is echoed by other AI leaders including Elon Musk and Google's AI boss Demis Hassabis.

However, not everybody is convinced. Cognitive scientist Gary Marcus, and cardiologist and digital medicine expert Eric Topol point out that current AI models lack the deep causal and biological understanding required to reliably yield breakthrough cures, and as of 2026, no AI-designed drug has achieved full clinical adoption.

"Setting an unattainable objective. I wish it would come true, but curing all these diseases in the next 10 years is impossible. And I'm very optimistic about the impact of AI for improving health," said Topol, in a post on X.

Marcus added that "most likely none of these will be 'relics of the past in ten years'”.

Anthropic CEO Has Long Predicted AI Could Transform Healthcare

Also read: AI-Created Virus Injected Into A Human For The First Time To Fight Antibiotic Resistance

This is not the first time Amodei has spoken about AI's potential to transform healthcare. In a post on X, he wrote: “I think it will actually be possible to cure most human disease in ~5-10 years.”

In two of his essays, Amodei discussed how advanced AI could accelerate biological and medical research, potentially compressing 50–100 years of scientific progress into five to 10 years.

His predictions have covered several major health conditions, including:

• Cancer
• Alzheimer's disease
• Genetic diseases
• Heart disease, diabetes and obesity
• Schizophrenia
• Major depression

He has also discussed the possibility of AI helping humans live significantly longer.

Anthropic's Expanding Healthcare Initiatives

Read More: Anthropic Says Claude Blocked Bird Flu, Chikungunya Research: How AI Could Enable Biological Misuse

In September, Anthropic partnered with medical knowledge platform OpenEvidence to provide AI-powered clinical decision support to healthcare providers in dozens of low- and middle-income countries.

OpenEvidence uses peer-reviewed research and treatment guidelines to answer doctors' clinical questions, with the initiative expected to reach about 100 countries, including Uganda, Angola, Sudan, Haiti and Mongolia.

Anthropic has also announced a Claude-led discovery of a molecular machine that researchers suspect could represent a new gene-editing mechanism, highlighting AI's potential to accelerate biological research.

What Are The Ethical Risks Of Using AI In Healthcare?

READ: AI Creates 16 Viruses To Kill Drug-Resistant E. coli, Raises Biosafety Concerns

Major technology companies, including Google, are increasingly expanding their presence in healthcare through AI-powered tools and services. However, the growing use of AI in medicine also raises questions about patient safety, privacy and accountability.

The World Health Organization (WHO) has called for stronger ethical oversight of AI-related health research.

In a recent report, WHO warned that rapid advances in AI are creating challenges around privacy, bias, fairness, transparency and accountability. It said existing research ethics systems may need additional expertise to assess risks associated with AI and large datasets.

Dr Rajeev Jayadevan, former president of IMA Cochin and convener of the Research Cell, Kerala, told HealthandMe that AI-driven research, particularly when it involves large datasets crossing national borders, may require ethics committees to include experts in computer science, data ethics and bioinformatics.

“Ethics Committees by themselves will need to be upgraded to incorporate computer scientists, data ethicists, and bioinformaticians.”

WHO also said oversight should extend beyond ethics committees to researchers, funders, scientific journals, data governance bodies, professional societies and regulators.

Delhi continues to battle high PM2.5 levels, even as a new study estimates that meeting the World Health Organization's (WHO) air quality guidelines could prevent or postpone 9.4 million deaths annually across 136 low- and middle-income countries (LMICs).

Following Diwali celebrations on November 8, PM2.5 concentrations in several parts of the capital reportedly exceeded 66 times the WHO's recommended 24-hour guideline. By November 11, Delhi's AQI had improved to below 300, in the 'poor' category, after several days in the 'very poor' and 'severe' categories.

Led by University of Cambridge researchers, the modelling study also found that cleaner air could reduce disease burden, healthcare costs and productivity losses.

What Did The Study Find?

Also read: PM2.5 Levels 66x WHO Limit In Delhi: How Air Pollution Could Affect Children's Lung Development

Published in Environment International, the study assessed the health and economic benefits of reducing PM₂.₅ and nitrogen dioxide (NO₂) levels across 136 LMICs.

Researchers used pollution, population and health data to model the impact of meeting WHO air quality guidelines and interim targets.

The findings suggest that meeting WHO guidelines could:

• Prevent or postpone 9.4 million deaths annually linked to PM₂.₅
• Prevent or postpone 1.1 million deaths linked to NO₂
• Reduce deaths associated with PM₂.₅ by an estimated 6.6 million and those associated with NO₂ by 435,000, even under less stringent interim targets

Meeting PM₂.₅ guidelines could also mean fewer new cases of:

• COPD: 2.8 million
• Dementia: 1.1 million
• Coronary heart disease: 7.3 million
• Stroke: 2.3 million

Cleaner Air Could Save Billions

Read More: Delhi AQI Crosses 2,000 Mark After Diwali: What Happens To Your Body Within Hours Of Exposure?

The researchers also estimated substantial economic benefits from meeting PM₂.₅ guidelines.

Annual direct medical cost savings could include:

• $11.8 billion for coronary heart disease
• $5.9 billion for stroke
• $8.6 billion for dementia

Productivity gains could reach $17.9 billion for stroke, $18.1 billion for COPD and $5.3 billion for coronary heart disease annually.

"Meeting the WHO's air quality guideline values will not be straightforward, but low- and middle-income countries have a critical opportunity to shape healthier futures as their populations grow and their cities expand," said Dr Haneen Khreis of IMS Epidemiology at Cambridge.

She called for better decisions on transport, urban planning and energy, saying these could significantly improve air quality and reduce pollution-related diseases.

What Causes PM2.5 And NO₂ Pollution?

Outdoor air pollution is a major environmental health risk, linked to respiratory and cardiovascular diseases, including asthma, COPD, heart disease and stroke, as well as dementia.

In 2021, the WHO revised its air quality guidelines, setting recommended limits for pollutants including PM₂.₅ and NO₂.

PM₂.₅ consists of particles measuring 2.5 micrometers or smaller. They can travel deep into the lungs. Major sources include vehicle exhaust, power plants, industrial emissions and construction dust. These particles can also form through chemical reactions in the atmosphere.

NO₂ is mainly produced by burning fossil fuels. Sources include vehicle exhaust, industrial emissions and gas stoves and heaters.

Air pollution is a particularly serious challenge in LMICs, where rapid urbanisation, economic development and increasing vehicle use have contributed to poor air quality.